Oracle Reports Q4 Earnings Today — A $553 Billion Backlog Meets Its First Real Conversion Test
ORCL is the most important print of the week. Here’s what the numbers actually mean.
Anthropic’s Near-Trillion Dollar IPO Filing Is Repricing Everything. Here’s What Investors Actually Own.
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn’t Anthropic — it’s what this does to the listed AI complex.
The PPI just hit 6.5% and the Fed has a real problem
June 12, 2026 Wholesale Prices Are Running Hot Again What the May PPI means for rates, gold, and Newmont ($NEM)…
AI Needs a Lot of Electricity. The Grid Can’t Keep Up. Here’s Where the Money Is Going.
The power bottleneck is the most underpriced constraint in the AI buildout — and utilities are finally getting noticed.
GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
Oracle beat. Then dropped 10%. Here is what nobody is talking about.
June 11, 2026 Oracle Beat Earnings and Still Got Punished The numbers were good. The reaction was worse. Here is…
Marvell Just Got Called the Next Trillion-Dollar Company. Here’s What the Numbers Actually Say.
MRVL posted record revenue and a wave of analyst upgrades. The question is whether the tape has already priced the future.
Goldman Sachs Just Repriced. The Question Is Whether It Deserves To Stay There.
Record equities, a four-year-high M&A backlog, and a SpaceX IPO mandate — GS is firing on almost every cylinder. Almost.
QCOM just got sold off with the wrong crowd
June 10, 2026 QCOM Got Lumped In. That Might Be the Opportunity. Edge-AI chips, a June 24 catalyst, and a…
The Healthcare Sector Has Been Left for Dead. That’s the Setup Bargain Hunters Have Been Waiting For.
Three years of underperformance, a 20% valuation discount, and a mean-reversion case that’s getting harder to ignore.